日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)

I(b)期研究评估肿瘤内激动剂抗CD40(selicrelumab)联合抗PD-L1(atezolizumab)治疗难治性或复发性B细胞淋巴瘤患者的安全性和有效性(ITSELF试验)

Alshatti, N; Lemonnier, F; Bachy, E; Lopez, J; Llamas, F; Damotte, D; Burron, B; Velut, Y; Mauduit, C; de Charette, M; Roussel, M; Palard, X; Marabelle, A; Huot, R

First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours

首次人体1期剂量递增研究,评估抗VISTA单克隆抗体W0180联合或不联合帕博利珠单抗治疗局部晚期或转移性实体瘤患者的疗效。

Gomez-Roca, Carlos; Champiat, Stéphane; Danlos, Francois-Xavier; Castañón Álvarez, Eduardo; Cassier, Philippe Alexandre; Dupuy, Elena; Jegou, David; Primard, Marie; Pétain, Aurélie; Saccareau, Mathilde; Gueguen-Dorbes, Geneviève; Fabre, Claire; Marabelle, Aurélien; Melero, Ignacio

Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA

抗PD-1疗法治疗结外NK/T细胞淋巴瘤的疗效:来自LYSA研究的匹配队列分析

Marouf, Amira; Chaubard, Sammara; Liévin, Raphaël; Michot, Jean-Marie; Molinari, Nicolas; Rossignol, Julien; Cavalieri, Doriane; Golfier, Camille; Allangba, Olivier; Philippe, Laure; Tessoulin, Benoît; Chauchet, Adrien; Deau, Bénédicte; Oberic, Lucie; Vargaftig, Jacques; Moignet, Aline; Clavert, Aline; Dulery, Rémy; Brisou, Gabriel; Tardy, Stéphanie; Fataccioli, Virginie; Houot, Roch; Casasnovas, René O; Thieblemont, Catherine; Ghesquières, Hervé; Carras, Sylvain; Le Gouill, Steven; Cartron, Guillaume; Ribrag, Vincent; Cheminant, Morgane; Marçais, Ambroise; Suarez, Felipe; Marabelle, Aurélien; Tournilhac, Olivier; Damaj, Gandhi; Gaulard, Philippe; De Leval, Laurence; Lemonnier, François; Bachy, Emmanuel; Chevret, Sylvie; Hermine, Olivier; Couronné, Lucile; Jaccard, Arnaud

Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers

Nanrilkefusp alfa (SOT101) 是一种 IL-15 受体 βγ 超激动剂,可作为单药或与抗 PD-1 药物联合用于治疗晚期癌症患者。

Stephane Champiat ,Elena Garralda ,Vladimir Galvao ,Philippe A Cassier ,Carlos Gomez-Roca ,Iphigenie Korakis ,Peter Grell ,Aung Naing ,Patricia LoRusso ,Romana Mikyskova ,Nada Podzimkova ,Milan Reinis ,Kaissa Ouali ,Andreu Schoenenberger ,Joachim Kiemle-Kallee ,Sascha Tillmanns ,Richard Sachse ,Ulrich Moebius ,Radek Spisek ,David Bechard ,Lenka Palova Jelinkova ,Irena Adkins ,Aurelien Marabelle

Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma

纳武利尤单抗血浆浓度和清除率与肾细胞癌患者的总生存期相关

Maritaz, Christophe; Combarel, David; Dalban, Cécile; Blondel, Louis; Broutin, Sophie; Marabelle, Aurelien; Albiges, Laurence; Paci, Angelo

Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors

STING激动剂E7766治疗晚期实体瘤的I期剂量递增和药效学研究

Luke, Jason J; Pinato, David J; Juric, Dejan; LoRusso, Patricia; Hosein, Peter J; Desai, Anupam M; Haddad, Robert; de Miguel, María; Cervantes, Andrés; Kim, Won Seog; Marabelle, Aurélien; Zhang, Yan; Rong, Yuanxin; Yuan, Xiaobin; Champiat, Stéphane

Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade

单次注射免疫检查点阻断剂后迅速发生的免疫相关不良事件

Guitton, Romain; Laparra, Ariane; Chanson, Noemie; Champiat, Stephane; Danlos, Francois-Xavier; Michot, Jean-Marie; Messayke, Sabine; Marabelle, Aurelien; Lambotte, Olivier

Expanded senescent CD8 T cells in IMID patients are associated with distinct inflammatory cytokines

IMID患者体内扩增的衰老CD8 T细胞与特定的炎症细胞因子相关

Naigeon, Marie; Bitoun, Samuel; Roulleaux Dugage, Matthieu; de Oliveira, Caroline; Berthot, Caroline; Besse, Benjamin; Marabelle, Aurélien; Danlos, François-Xavier; Mariette, Xavier; Chaput, Nathalie; Nocturne, Gaetane

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

CEA-CD3双特异性抗体cibisatamab联合或不联合atezolizumab治疗CEA阳性实体瘤患者:两项多中心I期试验的结果

Segal, Neil H; Melero, Ignacio; Moreno, Victor; Steeghs, Neeltje; Marabelle, Aurelien; Rohrberg, Kristoffer; Rodriguez-Ruiz, Maria E; Eder, Joseph P; Eng, Cathy; Manji, Gulam A; Waterkamp, Daniel; Leutgeb, Barbara; Bouseida, Said; Flinn, Nick; Das Thakur, Meghna; Elze, Markus C; Koeppen, Hartmut; Jamois, Candice; Martin-Facklam, Meret; Lieu, Christopher H; Calvo, Emiliano; Paz-Ares, Luis; Tabernero, Josep; Argilés, Guillem

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

癌症免疫治疗学会 (SITC) 关于肿瘤内免疫治疗临床试验 (IICT) 的建议:从癌前病变到转移性疾病

Luke, Jason J; Davar, Diwakar; Andtbacka, Robert H; Bhardwaj, Nina; Brody, Joshua D; Chesney, Jason; Coffin, Robert; de Baere, Thierry; de Gruijl, Tanja D; Fury, Matthew; Goldmacher, Gregory; Harrington, Kevin J; Kaufman, Howard; Kelly, Ciara M; Khilnani, Anuradha D; Liu, Ke; Loi, Sherene; Long, Georgina V; Melero, Ignacio; Middleton, Mark; Neyns, Bart; Pinato, David J; Sheth, Rahul A; Solomon, Stephen B; Szapary, Philippe; Marabelle, Aurelien